효소결합면역흡착측정법(ELISA) 검사 시장 : 제품 유형별, 검사 유형별, 용도별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Enzyme-linked Immunosorbent Assay Testing Market is projected to grow by USD 971.88 million at a CAGR of 7.33% by 2032.

Enzyme-linked immunosorbent assay testing remains a foundational technology for clinical diagnostics, public health surveillance, pharmaceutical research, veterinary health, food safety, and environmental monitoring. ELISA testing is widely used because it can detect and quantify antigens, antibodies, hormones, cytokines, allergens, toxins, and infectious disease markers through established laboratory workflows and adaptable direct, indirect, sandwich, and competitive assay formats.

For diagnostic and reference laboratory leaders, the market is being shaped by demand for high-throughput immunoassay testing, standardized quality systems, and faster clinical decision support. Continued use by public health agencies, regulated laboratories, academic medical centers, and biopharmaceutical research organizations reinforces ELISA as a trusted platform where analytical sensitivity, specificity, reproducibility, traceability, and cost-effective scalability are critical purchasing criteria.

Transformative Shifts in the ELISA Testing Landscape

The ELISA testing landscape is shifting from manual, batch-oriented workflows toward automated, digitally connected, and quality-controlled laboratory operations. Laboratories are increasingly pairing microplate readers, automated washers, liquid handling systems, laboratory information systems, and validated software to reduce variability, improve documentation, and support higher sample volumes across clinical and research settings.

Regulatory expectations are also transforming the market. ISO 15189 accreditation, CLIA requirements in the United States, CLSI guidance, and the European Union In Vitro Diagnostic Regulation emphasize traceability, performance verification, risk management, clinical evidence, and documentation. These forces are making assay validation, lot-to-lot consistency, internal controls, calibration practices, and proficiency testing central to competitive differentiation.

Cumulative Impact of Artificial Intelligence on ELISA Testing

Artificial intelligence is adding cumulative value across the ELISA testing workflow rather than replacing validated immunoassay science. AI-enabled analytics can support plate image review, curve fitting, outlier detection, quality-control trending, reagent inventory planning, sample prioritization, and workload management when integrated with laboratory information systems and governed by validated protocols.

The greatest near-term impact is operational: fewer transcription errors, faster result review, improved flagging of anomalous wells, better longitudinal monitoring of assay performance, and stronger support for corrective and preventive actions. However, laboratories must apply AI within documented quality-management systems, including validation, audit trails, cybersecurity controls, explainability, data integrity, and human oversight to meet clinical and regulatory expectations.

Key Regional Insights for ELISA Testing

North America remains a high-value ELISA testing region because of mature clinical laboratory networks, CLIA-regulated testing, FDA oversight, public health surveillance programs, and strong biomedical research funding. Europe is shaped by IVDR implementation, ISO-aligned quality expectations, and demand for standardized evidence supporting assay performance across clinical diagnostics, research, transfusion safety, allergy testing, autoimmune disease assessment, and infectious disease applications.

Asia-Pacific is expanding through growing diagnostic infrastructure in China, India, Japan, South Korea, and Australia, with demand driven by infectious disease testing, chronic disease monitoring, vaccination programs, food safety, and biopharmaceutical research. Latin America is anchored by Brazil and Mexico, where national regulatory frameworks, reference laboratories, and public health programs influence adoption. The Middle East is investing in advanced healthcare systems, especially in Gulf countries where laboratory modernization and accreditation remain priorities, while Africa continues to prioritize infectious disease surveillance, laboratory network strengthening, donor-supported diagnostics, and accessible immunoassay platforms for decentralized health systems.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets benefit from rising healthcare access, expanding hospital networks, infectious disease monitoring, and regulatory alignment influenced by the ASEAN Medical Device Directive. The GCC is advancing ELISA testing through healthcare modernization, centralized procurement models, national laboratory strategies, and quality-focused diagnostic capacity building aligned with broader health system transformation initiatives.

The European Union is defined by IVDR, making clinical evidence, post-market surveillance, performance evaluation, and manufacturer accountability decisive for ELISA testing adoption. BRICS countries combine large patient populations with expanding local manufacturing, public health needs, and research capacity, supporting demand for scalable immunoassay platforms. G7 countries continue to lead in assay innovation, reference laboratory operations, biomedical funding, and regulatory maturity, while NATO member states also reinforce demand through biosecurity preparedness, infectious disease readiness, military health systems, and resilient diagnostic supply chains.

Key Country Insights for ELISA Testing Adoption

The United States leads through CLIA-certified laboratory capacity, FDA oversight, public health surveillance, academic research, and strong adoption of automated immunoassay workflows, while Canada emphasizes accredited testing, provincial laboratory coordination, and public health laboratory integration. Mexico and Brazil are important Latin American markets supported by hospital expansion, reference laboratories, infectious disease testing needs, and national regulatory agencies that shape diagnostic approvals and quality requirements.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show sustained demand through advanced clinical diagnostics, research networks, autoimmune and allergy testing, and IVDR-adjacent quality expectations, while Russia maintains demand in infectious disease, hospital testing, and regional laboratory services. China and India are expanding access, local production, and high-volume testing capacity; Japan and South Korea emphasize precision, automation, and stringent quality systems; and Australia combines accredited laboratory systems with strong public health surveillance, food safety monitoring, and biomedical research activity.

Actionable Recommendations for ELISA Testing Leaders

Industry leaders should prioritize workflow automation, validated digital connectivity, and quality-management maturity before scaling ELISA testing capacity. Investments in microplate automation, standardized controls, lot verification, proficiency testing, preventive maintenance, staff competency programs, and LIS integration can improve throughput while reducing preventable errors.

Organizations should also build AI governance into laboratory operations, including validation, cybersecurity, audit trails, data integrity controls, documented human review, and change management. Strategic sourcing should emphasize reagent continuity, supplier qualification, cold-chain resilience, alternative supply planning, and regulatory readiness across FDA, IVDR, ISO 15189, CLIA, and CLSI-aligned environments.

Research Methodology for ELISA Testing Intelligence

This executive summary is based on structured secondary research, regulatory review, and market intelligence synthesis across clinical diagnostics, life sciences, public health, food safety, veterinary testing, and laboratory automation. Sources considered include publicly available guidance and frameworks from national and international health authorities, regulatory agencies, standards organizations, accreditation bodies, and peer-reviewed scientific literature.

The methodology emphasizes verified signals rather than unsupported estimates. Regional, group, and country insights were assessed through regulatory direction, laboratory infrastructure, healthcare investment trends, infectious disease surveillance needs, quality-system adoption, public health priorities, and documented adoption patterns for immunoassay automation and laboratory information systems.

Conclusion: ELISA Testing Positioned for Quality-Led Growth

ELISA testing continues to be a resilient, clinically relevant, and commercially important immunoassay platform. Its strength lies in validated science, broad analyte coverage, adaptable formats, established quality controls, and compatibility with automated laboratory workflows.

The next phase of leadership in enzyme-linked immunosorbent assay testing will depend on quality, connectivity, regulatory readiness, supply-chain resilience, and responsible AI adoption. Laboratories and suppliers that combine assay reliability with automation, traceability, and data-driven operations will be best positioned to meet rising needs across diagnostics, research, public health, food safety, veterinary health, and biosecurity applications.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Enzyme-linked Immunosorbent Assay Testing Market, by Product

• 7.1. Instruments
  • 7.1.1. Microplate Readers
  • 7.1.2. Microplate Washers
• 7.2. Kits
  • 7.2.1. Automated Kits
  • 7.2.2. Manual Kits
• 7.3. Reagents
  • 7.3.1. Antibodies
  • 7.3.2. Enzymes
  • 7.3.3. Substrates
• 7.4. Software And Services
  • 7.4.1. Data Analysis Software
  • 7.4.2. Maintenance Services

8. Enzyme-linked Immunosorbent Assay Testing Market, by Assay Type

• 8.1. Competitive
• 8.2. Direct
• 8.3. Indirect
• 8.4. Sandwich

9. Enzyme-linked Immunosorbent Assay Testing Market, by Application

• 9.1. Disease Testing
• 9.2. Drug Discovery
• 9.3. Environmental Testing
• 9.4. Food Safety And Quality

10. Enzyme-linked Immunosorbent Assay Testing Market, by End Users

• 10.1. Academic And Research
• 10.2. Contract Research Organizations
• 10.3. Hospitals And Diagnostics
• 10.4. Pharmaceutical And Biotech

11. Enzyme-linked Immunosorbent Assay Testing Market, by Distribution Channel

• 11.1. Online
• 11.2. Offline

12. Enzyme-linked Immunosorbent Assay Testing Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Enzyme-linked Immunosorbent Assay Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Enzyme-linked Immunosorbent Assay Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Agilent Technologies Inc.
• 16.3. ANP Technologies, Inc.
• 16.4. Autobio Diagnostics Co., Ltd.
• 16.5. Becton, Dickinson and Company
• 16.6. Bio-Rad Laboratories, Inc.
• 16.7. Bio-Techne Corporation
• 16.8. BioLegend, Inc.
• 16.9. bioMerieux S.A.
• 16.10. Biosurfit SA
• 16.11. Boditech Med Inc.
• 16.12. Charles River Laboratories International, Inc.
• 16.13. Danaher Corporation
• 16.14. Epitope Diagnostics Inc.
• 16.15. F. Hoffmann-La Roche AG
• 16.16. Fapon Biotech Inc.
• 16.17. Gyros Protein Technologies AB by Mesa Laboratories, Inc.
• 16.18. H.U. Group Holdings Inc.
• 16.19. J. Mitra & Co. Pvt. Ltd.
• 16.20. Kamiya Biomedical Company
• 16.21. Merck KGaA
• 16.22. MiCo BioMed, Inc.
• 16.23. Nanomix, Inc.
• 16.24. Promega Corporation
• 16.25. QIAGEN N.V.
• 16.26. Quanterix Corporation
• 16.27. QuidelOrtho Corporation
• 16.28. Randox Laboratories Ltd.
• 16.29. Revvity, Inc.
• 16.30. Shenzhen Micropoint Biotechnologies Co., Ltd.
• 16.31. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 16.32. Siemens Healthineers AG
• 16.33. Sysmex Corporation
• 16.34. Tecan Trading AG
• 16.35. Thermo Fisher Scientific Inc.
• 16.36. Tosoh Corporation
• 16.37. WAK-Chemie Medical GmbH
• 16.38. Zoetis Inc.
• 16.39. Zybio Inc.